Evidence-based·Last reviewed May 30, 2026·How we grade evidence

Lactobacillus crispatus

ProbioticLactobacillusBest before bed

Useful mainly for women preventing recurrent bacterial vaginosis or restoring vaginal microbiota.

Quick decision guide

May help most

women preventing recurrent bacterial vaginosis or restoring vaginal microbiota

Common dosing range

1-10 billion CFU/day (oral or vaginal)

When to expect effects

Weeks (often cyclic use)

Watch out for

Severely immunocompromised people should consult a clinician first.

What is it

Lactobacillus crispatus is a lactic acid-producing bacterium and a dominant member of the healthy human vaginal microbiota. It is commonly used as a probiotic strain in supplements targeting vaginal and urogenital health.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have recurrent bacterial vaginosis and want to reduce relapses

You want to restore an L. crispatus-dominant vaginal microbiome after antibiotics

You can use a strain-specified product, vaginally for more reliable colonization

Probably skip if…

You have an untreated acute infection needing antibiotics first

You are severely immunocompromised without clinician input

You expect it to reliably prevent UTIs (evidence is weaker there)

Evidence at a glance

Goal	Effect	Best fit	Time
bacterial vaginosis recurrence prevention Good Evidence	Lower recurrence rate	women with recurrent BV, typically after standard antibiotic treatment	Weeks
vaginal microbiome restoration Good Evidence	Increased L. crispatus dominance / lower pH	women re-establishing a Lactobacillus-dominant microbiota after disruption	Weeks
recurrent urinary tract infections Limited Evidence	Uncertain	women with recurrent UTIs seeking an adjunct	Weeks

bacterial vaginosis recurrence prevention

Good Evidence

Effect: Lower recurrence rate
Best fit: women with recurrent BV, typically after standard antibiotic treatment
Time: Weeks

vaginal microbiome restoration

Good Evidence

Effect: Increased L. crispatus dominance / lower pH
Best fit: women re-establishing a Lactobacillus-dominant microbiota after disruption
Time: Weeks

recurrent urinary tract infections

Limited Evidence

Effect: Uncertain
Best fit: women with recurrent UTIs seeking an adjunct
Time: Weeks

Evidence for 3 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

bacterial vaginosis recurrence prevention

Supplement benefit

Good Evidence

Randomized trials, especially of vaginal L. crispatus after antibiotic therapy, show reduced bacterial vaginosis recurrence compared with placebo. The bacterium lowers vaginal pH and competitively excludes pathogens, supporting durability of treatment. Trials vary by strain and delivery route, so effect size is moderate rather than uniform.

Effect size

Lower recurrence rate

Time to effect

Weeks

Best fit

women with recurrent BV, typically after standard antibiotic treatment

Bottom line: Reduces BV recurrence when used after standard treatment, especially vaginally.

SourceCarter et al., 2023 — PMC Mändar et al., 2023 — PubMed

vaginal microbiome restoration

Biomarker support

Good Evidence

Trials show vaginal L. crispatus can colonize and shift the microbiota toward a protective L. crispatus-dominant state (community state type I) with lower pH. Vaginal delivery produces more reliable colonization than oral. This is largely a microbiome/pH endpoint that underlies, but is distinct from, symptom outcomes.

Effect size

Increased L. crispatus dominance / lower pH

Time to effect

Weeks

Best fit

women re-establishing a Lactobacillus-dominant microbiota after disruption

Bottom line: Can restore a protective L. crispatus-dominant vaginal microbiome, especially given vaginally.

SourceHemmerling et al., 2025 — PMC Yang et al., 2020 — PMC

recurrent urinary tract infections

Supplement benefit

Limited Evidence

An L. crispatus-dominant vaginal microbiota is associated with lower UTI risk, and a vaginal L. crispatus product has shown reduced recurrent UTIs in at least one trial. Overall evidence is limited and less consistent than for BV. Benefit for UTIs should be considered preliminary.

Effect size

Uncertain

Time to effect

Weeks

Best fit

women with recurrent UTIs seeking an adjunct

Bottom line: May help reduce recurrent UTIs, but evidence is limited.

SourceStapleton et al., 2011 — PMC Czaja et al., 2007 — PMC

How it works

L. crispatus produces lactic acid (lowering vaginal pH to 3.5-4.5) and hydrogen peroxide, both of which inhibit growth of pathogenic bacteria and yeast. It also produces bacteriocins and forms adherent biofilms on the vaginal epithelium that physically exclude pathogens. L. crispatus-dominant vaginal microbiota (community state type I) is associated with lower risk of bacterial vaginosis, urinary tract infections, sexually transmitted infections, and preterm birth. Oral and vaginal probiotic delivery routes have both been studied; vaginal application produces more reliable colonization.

How to take it

1. Typical dose

1-10 billion CFU/day, oral or vaginal per product

2. Timing

Once daily; vaginal forms often at night

3. With food

with or without food (oral)

4. How long to try

Often cyclic (e.g., post-antibiotic or post-menses) over weeks

What to track

BV recurrence/symptoms (discharge, odor)

vaginal pH if measured

tolerance (GI or local irritation)

2 commercial forms

Compare the main delivery options and what they’re best suited for.

Vaginal capsule or suppository

Most evidence-based delivery route for vaginal health.

Direct delivery to target site

Oral capsule

More convenient but variable colonization.

Some strains translocate to vagina from gut

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

transient GI symptoms (oral)local irritation (vaginal)

Serious risks

rare bacteremia in severely immunocompromised individuals

Who should avoid it

severely immunodeficient people, those with central venous catheters, or recent surgery without clinician input

Pregnancy & breastfeeding

Vaginal L. crispatus has been used in pregnancy trials without apparent harm, but consult an obstetrician first.

Interactions

antibioticsMinor

antibiotics may kill the strain; separate dosing by 2-3 hours and continue through the course

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

specific strain designation (e.g., LMG P-31003, LCR01)

guaranteed CFU through expiry

delivery route stated (oral vs vaginal)

Be skeptical of…

cures all vaginal infections

replaces antibiotics for active infection

generic 'feminine balance' hype without strain data

Frequently asked questions

Is L. crispatus safe to take during pregnancy?⌄

Some trials have used L. crispatus probiotics during pregnancy without apparent harm, but pregnant women should consult their obstetrician before starting any probiotic.

How long does it take to work?⌄

For BV recurrence prevention, trials typically show benefits over 12-24 weeks of use following antibiotic treatment.

References by claim

bacterial vaginosis recurrence prevention

Carter et al., 2023 — PMC (2023) link

Mändar et al., 2023 — PubMed (2023) link

vaginal microbiome restoration

Hemmerling et al., 2025 — PMC (2025) link

Yang et al., 2020 — PMC (2020) link

recurrent urinary tract infections

Stapleton et al., 2011 — PMC (2011) link

Czaja et al., 2007 — PMC (2007) link

Track Lactobacillus crispatus with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.